Product Candidate | Target | Load | Indication/Treatment | Development Phase |
Pre-clinical Phase I Phase II Phase III/ |
||||
Naked | Relapsed/Refractory High-Risk Neuroblastoma (Pediatric) |
|
||
Naked | Relapsed/Refractory High-Risk Neuroblastoma (Pediatric) |
|
||
Naxitamab | GD2 | Naked | (Front-Line) High-Risk Neuroblastoma (Pediatric) |
|
Naked | Relapsed (Second-Line) Osteosarcoma |
|
||
Naked | Chemoimmunotherapy for Relapsed/Refractory High-Risk Neuroblastoma |
|
||
131I | CNS/Leptomeningeal Metastases from Neuroblastoma (Pediatric) |
|
||
Omburtamab | B7-H3 | 131I | Intrathecal Immunotherapy for CNS/Leptomeningeal Metastases |
|
124I | Diffuse Intrinsic Pontine Glioma (Pediatric) |
|
||
131I | Desmoplastic Small Round Cell Tumor (Pediatric) |
|
||
Omburtamab-DTPA | B7-H3 | 177Lu | B7-H3 Positive CNS/Leptomeningeal Solid Tumors |
|
huB7-H3 | B7-H3 | TBD | Systemic Solid Tumors (Adult) (Third-Line) |
|
huGD2-BsAb | GD2xCD3 | Naked | Refractory GD2-Positive Solid Tumors |
|
huCD33-BsAb | CD33xCD3 | Naked | Hematological Cancers Expressing CD33 |
|
Y-mAbs Therapeutics, Inc (Y-mAbs) is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center (“MSK”) under an exclusive worldwide license and research collaboration agreement. Y-mAbs applies its world-class antibody capabilities to create life-changing immunotherapies for cancer patients of all ages. Y-mAbs’ innovative product candidates leverage its extensive drug development capabilities and its proprietary protein technology platform – MULTI TAG™.
Our Mission is to become the world leader in developing better and safer antibody based pediatric oncology products addressing clear unmet medical needs. We will expand into certain adult cancer indications and advance these in collaboration with partners.
Please insert contact information and specifics regarding diagnose to be contacted regarding treatment opportunities in Y-mAbs’ clinical trials